Post by STADA Group

STADA is further strengthening its commitment to patient access to high-quality biologic medicines in Europe. We have signed an agreement with CuraTeQ under which STADA gains rights to market and distribute pegfilgrastim and filgrastim biosimilars in European markets. CuraTeQ remains responsible for development, regulatory affairs, manufacturing and supply. This collaboration expands our biosimilar offering and supports better treatment options for patients across Europe. Read more in our press release:  https://lnkd.in/dBRtmNgh #STADANews